Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mundipharma Satisfies Appetite For Piece Of $4.5bn Pegfilgrastim Pie With Cinfa Biotech Buy

Executive Summary

Mundipharma widens its biosimilar portfolio by acquiring Cinfa Biotech, and its soon-to-be-launched pegfilgrastim biosimilar.


Related Content

Deal Watch, M&A: Warp Drive And Its Partnerships Acquired By Revolution
Mylan Head Of Biologics Chrys Kokino On Fulphila Launch And US Biosimilars
Biosimilar Infliximab Success Paves The Way For Adalimumab In Europe
EU First For Pegfilgrastim Biosimilars? EMA Decides This Week
Cinfa MD Discusses Biosimilar Products Approaching The Market
Mundipharma Acquires 'Smart' Chemo Drug From CellAct


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts